587 related articles for article (PubMed ID: 11884480)
21. Osteopontin attenuates acute gastrointestinal graft-versus-host disease by preventing apoptosis of intestinal epithelial cells.
Kawakami K; Minami N; Matsuura M; Iida T; Toyonaga T; Nagaishi K; Arimura Y; Fujimiya M; Uede T; Nakase H
Biochem Biophys Res Commun; 2017 Apr; 485(2):468-475. PubMed ID: 28192120
[TBL] [Abstract][Full Text] [Related]
22. Reactivity of hybridomas derived from T cells activated in vivo during graft-versus-host disease.
Leibnitz RR; Lipsky PE; Thiele DL
J Immunol; 1994 Dec; 153(11):4959-68. PubMed ID: 7963559
[TBL] [Abstract][Full Text] [Related]
23. Role of immunoregulatory donor T cells in suppression of graft-versus-host disease following donor leukocyte infusion therapy.
Johnson BD; Becker EE; LaBelle JL; Truitt RL
J Immunol; 1999 Dec; 163(12):6479-87. PubMed ID: 10586039
[TBL] [Abstract][Full Text] [Related]
24. The role of host T cell subsets in bone marrow rejection directed to isolated major histocompatibility complex class I versus class II differences of bm1 and bm12 mutant mice.
Vallera DA; Taylor PA; Sprent J; Blazar BR
Transplantation; 1994 Jan; 57(2):249-56. PubMed ID: 7906058
[TBL] [Abstract][Full Text] [Related]
25. Histological characteristics of lupus nephritis in F1 mice with chronic graft-versus-host reaction across MHC class II difference.
Ito S; Ueno M; Nishi S; Arakawa M; Ikarashi Y; Saitoh T; Fujiwara M
Autoimmunity; 1992; 12(2):79-87. PubMed ID: 1617113
[TBL] [Abstract][Full Text] [Related]
26. Inhibition of graft-versus-host disease by double-negative regulatory T cells.
Young KJ; DuTemple B; Phillips MJ; Zhang L
J Immunol; 2003 Jul; 171(1):134-41. PubMed ID: 12816991
[TBL] [Abstract][Full Text] [Related]
27. T cell subsets involved in lethal graft-versus-host disease directed to immunodominant minor histocompatibility antigens.
Berger M; Wettstein PJ; Korngold R
Transplantation; 1994 Apr; 57(7):1095-102. PubMed ID: 7909395
[TBL] [Abstract][Full Text] [Related]
28. Ligation of OX40 (CD134) regulates graft-versus-host disease (GVHD) and graft rejection in allogeneic bone marrow transplant recipients.
Blazar BR; Sharpe AH; Chen AI; Panoskaltsis-Mortari A; Lees C; Akiba H; Yagita H; Killeen N; Taylor PA
Blood; 2003 May; 101(9):3741-8. PubMed ID: 12521997
[TBL] [Abstract][Full Text] [Related]
29. Split tolerance in spleen chimeras.
Sprent J; Hurd M; Schaefer M; Heath W
J Immunol; 1995 Feb; 154(3):1198-206. PubMed ID: 7822792
[TBL] [Abstract][Full Text] [Related]
30. Ductal lesions of exocrine glands and insulitis induced by L3T4+ T cells following graft-versus-host reaction due to major histocompatibility complex class II disparity.
Saitoh T; Fujiwara M; Asakura H
Clin Immunol Immunopathol; 1990 Dec; 57(3):339-50. PubMed ID: 1978809
[TBL] [Abstract][Full Text] [Related]
31. Polarized type 2 alloreactive CD4+ and CD8+ donor T cells fail to induce experimental acute graft-versus-host disease.
Krenger W; Snyder KM; Byon JC; Falzarano G; Ferrara JL
J Immunol; 1995 Jul; 155(2):585-93. PubMed ID: 7608537
[TBL] [Abstract][Full Text] [Related]
32. Donor CD8 cells prevent allogeneic marrow graft rejection in mice: potential implications for marrow transplantation in humans.
Martin PJ
J Exp Med; 1993 Aug; 178(2):703-12. PubMed ID: 8101864
[TBL] [Abstract][Full Text] [Related]
33. Rapamycin inhibits the generation of graft-versus-host disease- and graft-versus-leukemia-causing T cells by interfering with the production of Th1 or Th1 cytotoxic cytokines.
Blazar BR; Taylor PA; Panoskaltsis-Mortari A; Vallera DA
J Immunol; 1998 Jun; 160(11):5355-65. PubMed ID: 9605135
[TBL] [Abstract][Full Text] [Related]
34. T-cell activation and differentiation are regulated by TNF during murine DBA/2-->B6D2F1 intestinal graft-versus-host disease.
Brown GR; Thiele DL
J Clin Immunol; 2000 Sep; 20(5):379-88. PubMed ID: 11051280
[TBL] [Abstract][Full Text] [Related]
35. Increased entry into the IFN-gamma effector pathway by CD4+ T cells selected by I-Ag7 on a nonobese diabetic versus C57BL/6 genetic background.
Koarada S; Wu Y; Ridgway WM
J Immunol; 2001 Aug; 167(3):1693-702. PubMed ID: 11466393
[TBL] [Abstract][Full Text] [Related]
36. Intestinal graft-versus-host disease is initiated by donor T cells distinct from classic cytotoxic T lymphocytes.
Thiele DL; Eigenbrodt ML; Bryde SE; Eigenbrodt EH; Lipsky PE
J Clin Invest; 1989 Dec; 84(6):1947-56. PubMed ID: 2531761
[TBL] [Abstract][Full Text] [Related]
37. Prevention of allogeneic marrow graft rejection by donor T cells that do not recognize recipient alloantigens: potential role of a veto mechanism.
Martin PJ
Blood; 1996 Aug; 88(3):962-9. PubMed ID: 8704255
[TBL] [Abstract][Full Text] [Related]
38. Phenotypic analysis of donor cells infiltrating the small intestinal epithelium and spleen during graft-versus-host disease.
Schattenfroh NC; Hoffman RA; McCarthy SA; Simmons RL
Transplantation; 1995 Jan; 59(2):268-73. PubMed ID: 7839451
[TBL] [Abstract][Full Text] [Related]
39. The role of major histocompatibility complex and non-major histocompatibility complex encoded antigens in generation of bile duct lesions during hepatic graft-vs.-host responses mediated by helper or cytotoxic T cells.
Williams FH; Thiele DL
Hepatology; 1994 Apr; 19(4):980-8. PubMed ID: 8138273
[TBL] [Abstract][Full Text] [Related]
40. Fas-deficient lpr mice are more susceptible to graft-versus-host disease.
van Den Brink MR; Moore E; Horndasch KJ; Crawford JM; Hoffman J; Murphy GF; Burakoff SJ
J Immunol; 2000 Jan; 164(1):469-80. PubMed ID: 10605044
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
